• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Decline of onset-to-diagnosis interval and its impacts on clinical outcome of COVID-19 in China: a nation-wide observational study

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2022 Aug 5;22(1):674.
doi: 10.1186/s12879-022-07660-4.
Decline of onset-to-diagnosis interval and its impacts on clinical outcome of COVID-19 in China: a nation-wide observational study


Qing-Bin Lu[SUP] #[/SUP][SUP] 1 [/SUP], Tian-Le Che[SUP] #[/SUP][SUP] 2 [/SUP], Li-Ping Wang[SUP] 3 [/SUP], An-Ran Zhang[SUP] 2 4 [/SUP], Xiang Ren[SUP] 3 [/SUP], Tao Wang[SUP] 2 [/SUP], Meng-Jie Geng[SUP] 3 [/SUP], Yi-Fei Wang[SUP] 3 [/SUP], Meng-Yang Liu[SUP] 2 5 [/SUP], Hai-Yang Zhang[SUP] 2 [/SUP], Li-Qun Fang[SUP] 6 [/SUP], Wei Liu[SUP] 7 8 [/SUP], Zhong-Jie Li[SUP] 9 [/SUP]



Affiliations
Free article

Abstract

Background: To quantitatively assess the impact of the onset-to-diagnosis interval (ODI) on severity and death for coronavirus disease 2019 (COVID-19) patients.
Methods: This retrospective study was conducted based on the data on COVID-19 cases of China over the age of 40 years reported through China's National Notifiable Infectious Disease Surveillance System from February 5, 2020 to October 8, 2020. The impacts of ODI on severe rate (SR) and case fatality rate (CFR) were evaluated at individual and population levels, which was further disaggregated by sex, age and geographic origin.
Results: As the rapid decline of ODI from around 40 days in early January to < 3 days in early March, both CFR and SR of COVID-19 largely dropped below 5% in China. After adjusting for age, sex, and region, an effect of ODI on SR was observed with the highest OR of 2.95 (95% CI 2.37‒3.66) at Day 10-11 and attributable fraction (AF) of 29.1% (95% CI 22.2‒36.1%) at Day 8-9. However, little effect of ODI on CFR was observed. Moreover, discrepancy of effect magnitude was found, showing a greater effect from ODI on SR among patients of male sex, younger age, and those cases in Wuhan.
Conclusion: The ODI was significantly associated with the severity of COVID-19, highlighting the importance of timely diagnosis, especially for patients who were confirmed to gain increased benefit from early diagnosis to some extent.

Keywords: COVID-19; Case fatality rate; Onset-to-diagnosis interval; Severe rate.
 
Back
Top Bottom